about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Third Rock­'s Am­bys hauls $140M for liv­er dis­ease, ink­ing Take­da deal ahead of launch

7 years ago
Financing
Startups

Al­ler­gan picks up op­tion for Ed­i­tas' rare eye dis­ease drug; Cure­Ge­net­ics bags $17M

7 years ago
News Briefing

PAH ther­a­py tanks in Phase III, oblit­er­at­ing Bellerophon's stock

7 years ago
R&D

Pro­tag­o­nist rais­es $22M to re­vive PTG-100; Paratek's an­tibi­ot­ic shows non-in­fe­ri­or­i­ty

7 years ago
News Briefing

What's big­ger than a uni­corn? Sa­mumed stuns yet again as an­ti-ag­ing pipeline draws $438M at $12B val­u­a­tion

7 years ago
Financing

Te­va falls on dis­ap­point­ing sales fore­cast; Akcea and PTC take two drugs to Latin Amer­i­ca

7 years ago
News Briefing

Stock scan­dals: Biotech in­cu­ba­tor Fortress pur­chased bro­ker­age firm to tout its own star­tups — Reuters

7 years ago
Startups

The bar low­ers yet again for PRV prices, with Ky­owa/Ul­tragenyx sell­ing at $80.6M

7 years ago
Pharma

The Google of CRISPR tech? Tech leg­ends Tim Cook and Jeff Hu­ber back Mam­moth Bio­sciences

7 years ago
Financing
Startups

Faster, cheap­er DNA se­quenc­ing gets Om­niome $60M led by Chi­nese in­vestors

7 years ago
Financing
Startups

FDA ap­proves can­cer ra­di­a­tion drug Aze­dra, send­ing Prog­en­ics stock north

7 years ago
Pharma

As it fights loom­ing com­pe­ti­tion on Sub­ox­one, In­di­v­ior gets FDA OK on new schiz­o­phre­nia drug

7 years ago
Pharma

Tonix crash­es on PhI­II PTSD fail­ure, send­ing stock to the gut­ter

7 years ago
R&D

Days af­ter Mer­ck deal, Sutro rolls out $85M E round to fund in­ter­nal can­cer pipeline

7 years ago
Financing

On top of ex­pir­ing Her­ceptin patents, Roche faces huge roy­al­ty loss­es in 2019

7 years ago
Pharma

Months af­ter IPO, No­var­tis spin­out resTOR­bio wins on PhI­Ib da­ta — stock soars

7 years ago
R&D

With moth­ers on erec­tile dys­func­tion drug, 11 new­born ba­bies die af­ter tri­al trig­gers lung prob­lems

7 years ago
R&D

Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

7 years ago
Pharma

Il­lu­mi­na's found­ing sci­en­tist launch­es soft­ware start­up to track fast-mu­tat­ing hos­pi­tal bugs

7 years ago
People
Startups

Pfiz­er/Mer­ck KGaA launch sol­id tu­mor com­bo study with Leap; As­traZeneca and Im­munomedics to test ADC can­cer com­bo

7 years ago
News Briefing

Lil­ly inks R&D deal with An­i­ma, pay­ing $44M in re­search fund­ing and up­front pay­ments

7 years ago
R&D
Pharma

BMS part­ners with Grit­stone on sol­id tu­mor com­bos; Roche's Alzheimer's di­ag­nos­tic gets break­through sta­tus

7 years ago
News Briefing

Bat­tered and weary, Vi­cal flags for help fol­low­ing its line­up of lemons

7 years ago
R&D

So­bi signs $450M deal for rare dis­ease drug ema­palum­ab, boost­ing its in­flam­ma­tion, I/O pipeline

7 years ago
Pharma
First page Previous page 12345 Next page Last page
A service from the Financial Times